MannKind cites positive results for Technosphere insulin

By Elaine Rigoli

Tampa, Fla., Sept. 18 - MannKind Corp. said its phase 3 clinical study of inhaled insulin in patients with type 2 diabetes demonstrated that patients using Technosphere insulin achieved comparable improvements in glycemic control to patients treated with an injected rapid-acting insulin analog (RAA).

This study was designed to evaluate whether the MannKind Technosphere insulin system showed similar safety and efficacy compared to patients treated with insulin aspart (NovoLog), an injected RAA.

In addition, the Valencia, Calif., pharmaceutical company said it observed no adverse effect on pulmonary function in either treatment group.

However, unlike the injected RAA group, Technosphere insulin patients lost weight during the treatment period, according to a news release.

"The results of this first phase 3 efficacy study show that Technosphere insulin can be differentiated from other inhaled insulin systems. With the recent completion of enrollment of the major phase 3 safety study, all of our pivotal phase 3 trials are now well underway, suggesting that Technosphere insulin could be the next pulmonary insulin product to reach the market," chairman and chief executive officer Alfred Mann said in the release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.